Status:
COMPLETED
Sequential Therapy for Hypogonadotropic Hypogonadism
Lead Sponsor:
Shanghai Jiao Tong University School of Medicine
Conditions:
Hypogonadotropic Hypogonadism
Kallmann Syndrome
Eligibility:
MALE
16-45 years
Phase:
PHASE4
Brief Summary
The traditional therapy for induction of spermatogenesis in male hypogonadotropic hypogonadism requires both HCG and human menopausal gonadotropin (HMG) or FSH until pregnancy occurs. Because of the h...
Eligibility Criteria
Inclusion
- Clinical hypogonadotropic hypogonadism
- Hormonal levels: Testosterone \< 1.8ng/ml, LH \< 2-3 mIU/mL and FSH \< 2-3 mIU/mL
- Infantile testis
- Delayed bone age
- Normal testing of the anterior pituitary gland
Exclusion
- Prior therapy with HMG or FSH
- Severe dysfunction of live and kidney
- Cryptorchidism or no response to HCG stimulation experiment (Testosterone \< 1.8ng/ml after HCG stimulation)
- Another pituitary hormonal deficiency
- Hypergonadotropic hypogonadism
- With abnormal karyotype
Key Trial Info
Start Date :
September 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2012
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT01403532
Start Date
September 1 2009
End Date
December 1 2012
Last Update
February 11 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rui Jin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China, 200025